Siglec-15与肿瘤免疫关系的研究进展

Progress on the relationship between Siglec-15 and cancer immunotherapy

目的总结唾液酸结合免疫球蛋白样凝集素-15(Siglec-15)在肿瘤免疫领域的研究进展,以期为肿瘤免疫治疗提供新的理论依据。方法以“Siglec-15、肿瘤、免疫调节、信号通路、免疫治疗”为中文关键词,以“Siglec-15、tumor、immunoregulation、signal pathway、immunotherapy”为英文关键词,系统检索中国知网和PubMed数据库2013-01-01-2023-12-31发表的相关文献。纳入标准:(1)Siglec-15的发现及分子特征;(2)Siglec-15在肿瘤免疫调节中的作用机制及相关信号通路;(3)Siglec-15的免疫治疗前景。排除标准:低质量以及数据陈旧的文献。最终纳入51篇文献进行分析。结果现有研究表明,Siglec-15在多种肿瘤细胞以及肿瘤相关巨噬细胞(TAM)中均高表达。其通过抑制T细胞的活化和增殖来诱导肿瘤的免疫逃逸。此外,Siglec-15还可通过介导特定的分子信号通路调节肿瘤微环境。目前,多种具有抗肿瘤活性的Siglec-15相关药物正在积极开发中,这为肿瘤免疫治疗提供了新的思路。结论近年来,随着程序性死亡受体1(PD-1)及其配体(PD-L1)抗体耐药性问题的出现,Siglec-15可被认为是替代或协同抗PD-1/PD-L1治疗的新兴靶点,有望发挥重要作用。

Objective To summarize the research progress of sialic acid-binding immunoglobulin-like lectin-15(Siglec-15)in the field of tumor immunity,in order to provide a new theoretical basis for tumor immunotherapy.Methods“Siglec-15,tumor,immunoregulation,signal pathway,immunotherapy”was used as the key words to systematically search the literature published in China National Knowledge Infrastructure(CNKI)and PubMed database from 2013-01-01 to 2023-12-31.Inclusion criteria:(1)discovery and molecular characteristics of Siglec-15;(2)the mechanism of Siglec-15 in tumor immune regulation and related signaling pathways;(3)the prospect of Siglec-15 immunotherapy.Exclusion criteria:literature with low quality and obsolete data.A total of 51 articles were included for analysis.Results Existing research indicates that Siglec-15 is highly expressed in various tumor cells as well as tumor-associated macrophages(TAMs).It induces tumor immune evasion by suppressing the activation and proliferation of T cells.Additionally,Siglec-15 can regulate the tumor microenvironment by mediating specific molecular signal pathways.Currently,multiple Siglec-15-related drugs with anti-tumor activity are actively being developed,providing new avenues for tumor immunotherapy.Conclusion In recent years,with the emergence of resistance to programmed death-1(PD-1)and its ligand(PD-L1)antibodies,Siglec-15 is considered an emerging target that may serve as an alternative or synergistic approach to anti-PD-1/PD-L1 therapy,holding promise for significant contributions.